ScripVenture capital fundraising by biopharmaceutical firms in the second quarter was a mixed bag, according to Venture Monitor data from Pitchbook and the National Venture Capital Association (NVCA), wh
ScripEikon Therapeutics, Inc. came out of stealth mode with an icon at its helm last year and a venture capital mega-round to fund development of a technology platform that uses super-resolution microscop